Buddy Wilson - Grown Rogue VP Sales
GRUSF Stock | USD 0.70 0.01 1.41% |
Insider
Buddy Wilson is VP Sales of Grown Rogue International
Phone | 458 226 2100 |
Web | https://www.grownrogue.com |
Grown Rogue Management Efficiency
The company has return on total asset (ROA) of 0.1475 % which means that it generated a profit of $0.1475 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2575 %, meaning that it generated $0.2575 on every $100 dollars invested by stockholders. Grown Rogue's management efficiency ratios could be used to measure how well Grown Rogue manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Richard MD | Collegium Pharmaceutical | 64 | |
Mark Baldyga | Biofrontera | N/A | |
Hermann Lubbert | Biofrontera | 68 | |
Kevin MacDermott | cbdMD Inc | 62 | |
Marlo Manning | Collegium Pharmaceutical | N/A | |
Muthusamy RPh | ANI Pharmaceuticals | 56 | |
Rami Levy | INC Research Holdings | 59 | |
BComm BCom | Akanda Corp | 68 | |
Advocate Ohayon | INC Research Holdings | 35 | |
David Erickson | Evolus Inc | N/A | |
CCFP DipSportMed | Evolus Inc | 60 | |
Scott Sudduth | Collegium Pharmaceutical | N/A | |
Raymond Coffman | cbdMD Inc | 62 | |
Tejinder Virk | Akanda Corp | 42 | |
BCom BAcc | Akanda Corp | 44 | |
Jeff Holm | Biofrontera | N/A | |
Eugene III | Biofrontera | 39 | |
Alex Dasalla | Collegium Pharmaceutical | N/A | |
Elizabeth JD | ANI Pharmaceuticals | N/A | |
Thomas Flow | Akanda Corp | 46 | |
Amos Cohen | INC Research Holdings | 45 |
Management Performance
Return On Equity | 0.26 | |||
Return On Asset | 0.15 |
Grown Rogue International Leadership Team
Elected by the shareholders, the Grown Rogue's board of directors comprises two types of representatives: Grown Rogue inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Grown. The board's role is to monitor Grown Rogue's management team and ensure that shareholders' interests are well served. Grown Rogue's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Grown Rogue's outside directors are responsible for providing unbiased perspectives on the board's policies.
Buddy Wilson, VP Sales | ||
Steven Lightman, Special CEO | ||
Adam August, VP LLC | ||
Obie Strickler, CEO Pres | ||
Ryan Kee, Chief CFO |
Grown Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Grown Rogue a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.26 | |||
Return On Asset | 0.15 | |||
Profit Margin | 0.06 % | |||
Operating Margin | 0.20 % | |||
Current Valuation | 21.02 M | |||
Shares Outstanding | 170.63 M | |||
Shares Owned By Insiders | 22.76 % | |||
Shares Owned By Institutions | 16.71 % | |||
Price To Book | 3.47 X | |||
Price To Sales | 1.01 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Grown OTC Stock
Grown Rogue financial ratios help investors to determine whether Grown OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Grown with respect to the benefits of owning Grown Rogue security.